Overall, diverse experimental evidence from genetic screens strongly supports our identification of USP28 deletions as p53-loss phenocopying events, and our cancer genomic and transcriptomic analysis suggests a widespread distribution of causal USP28 deletions across human tumors. This evidence concerns the gene USP28 and cancer.